Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 2360Neoplasms 1709Prostatic Neoplasms 1201Lung Neoplasms 926Colorectal Neoplasms 886Carcinoma, Non-Small-Cell Lung 869Leukemia, Myeloid, Acute 593Pancreatic Neoplasms 578Multiple Myeloma 551Carcinoma, Hepatocellular 518Brain Neoplasms 516Neoplasm Metastasis 462Head and Neck Neoplasms 458Melanoma 417Ovarian Neoplasms 414Glioblastoma 403Precursor Cell Lymphoblastic Leukemia-Lymphoma 400Stomach Neoplasms 377Uterine Cervical Neoplasms 365Squamous Cell Carcinoma of Head and Neck 362Rectal Neoplasms 342Recurrence 337Sarcoma 327Hematologic Neoplasms 324Colonic Neoplasms 323Lymphoma 321Triple Negative Breast Neoplasms 291Carcinoma, Renal Cell 284Glioma 283Urinary Bladder Neoplasms 281

Interventions

irinotecan sucrosofate 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Malignant Ascites × 1 year × Clear all
NCT07490626 2026-03-27

Paracentesis

University of Utah

Phase NA Not yet recruiting
20 enrolled

Malignant Ascites

NCT07397819 2026-02-09

Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy

Sun Yat-sen University

Phase 1/2 Recruiting
48 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡